C16orf57 Inhibitors

Compounds like Pladienolide B, E7107, Dimethyl sulfoxide-d6, Meayamycin, Isoginkgetin, Eg5 Inhibitor III, Dimethylenastron, Spliceostatin A, and Herboxidiene exhibit their inhibitory effects by interacting with components of the spliceosome, such as the SF3b complex. By altering the function of the spliceosome, these chemicals can indirectly affect the splicing of U6 small nuclear RNA, which is a process that the C16orf57 protein is known to be involved in.

Other compounds listed, while not directly targeting the spliceosome, can influence cellular processes and pathways that may indirectly modulate C16orf57 activity. t-Butylhydroquinone, a phenolic antioxidant, can affect gene expression profiles, while Quercetin, a flavonoid, is known for its broad effects on signaling pathways, both of which can result in changes to the cellular environment that would impact C16orf57. Chloroquine, by altering endosomal acidification, could affect RNA processing pathways, thus having an indirect influence on C16orf57. Similarly, Etoposide acts on DNA topoisomerase II, potentially affecting the transcriptional landscape and subsequently the activity of C16orf57 due to changes in the availability or processing of RNA precursors.